Differential Effects of a First-in-Class IKKα Inhibitor on Trabecular and Cortical Bone in a Human Prostate Cancer Xenograft Model
Calcified Tissue International · 25.07.2026 · 117 (1)
DOI: 10.1007/s00223-026-01558-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Calcified Tissue International, online erschienen am 25.07.2026. Verfasst von Abdullah Al-Jeffery und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Metabolism, Medical School, Beech Hill Road, Sheffield, S10 2RX, England, UK. Hauptthemen laut MEDLINE: Prostatic Neoplasms, I-kappa B Kinase, Cancellous Bone, Bone and Bones. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Prostate Cancer UK.
Abstract (Originalsprache)
IKK_α, a key component of canonical and non-canonical NFκB signalling, is implicated in prostate cancer and bone metabolism. Here, we validated the anti-proliferative effects of selected molecules from a series of first-in-class IKK_α inhibitors against a panel of human prostate cancer models and then showed that the potent anti-tumour and highly IKK_α-selective SU^1349 reduced the ability of human PC3 cells to migrate and invade in vitro, induce osteolysis ex vivo, and cause trabecular bone loss in mice. Paradoxically, mice treated with SU^1349 exhibited cortical bone loss. Histomorphometrical in vivo and functional in vitro studies confirmed that SU^1349 suppressed osteoclastogenesis, but both enhanced and reduced osteoblast number and activity. Mechanistically, despite SU^1349 being an inhibitor with a significant selectivity for IKK_α over IKK_β, it inhibited both canonical and non-canonical NFκB signalling in PC3 cells, osteoclasts, and osteoblasts, and reduced the levels of several PC3-secreted, NFκB-regulated factors. This study suggests that IKK_α inhibitors could be of therapeutic value in the treatment of prostate cancer-induced osteolysis. However, osteoblast inhibition may limit their usefulness as osteoprotective agents. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology and Metabolism, Medical School, Beech Hill Road, Sheffield, S10 2RX, England, UK.
- Bone and Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, University of Edinburgh, Crewe Road, Edinburgh, EH4 2XR, Scotland, UK.
- Department of Life Sciences, European University Cyprus, Nicosia, Cyprus.
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0NR, Scotland, UK.
- Department of Oncology and Metabolism, Medical School, Beech Hill Road, Sheffield, S10 2RX, England, UK. aymen.idris@sheffield.ac.uk.
Förderung
- Cancer Research UK
- Prostate Cancer UK
Zitieren
APA
Al-Jeffery, A., Zeng, F., Sophocleous, A., Marino, S., Ponzetti, M., Capulli, M., Paul, A., Plevin, R., Fowles, A. C. M., Mackay, S. P., Rucci, N., & Idris, A. I. (2026). Differential Effects of a First-in-Class IKKα Inhibitor on Trabecular and Cortical Bone in a Human Prostate Cancer Xenograft Model. Calcified Tissue International, 117(1). https://doi.org/10.1007/s00223-026-01558-y
Vancouver
Al-Jeffery A, Zeng F, Sophocleous A, Marino S, Ponzetti M, Capulli M, et al. Differential Effects of a First-in-Class IKKα Inhibitor on Trabecular and Cortical Bone in a Human Prostate Cancer Xenograft Model. Calcified Tissue International. 2026;117(1). doi:10.1007/s00223-026-01558-y
BibTeX
@article{AlJeffery2026,
author = {Al-Jeffery, Abdullah and Zeng, Feier and Sophocleous, Antonia and Marino, Silvia and Ponzetti, Marco and Capulli, Mattia and Paul, Andrew and Plevin, Robin and Fowles, Ann C M and Mackay, Simon P and Rucci, Nadia and Idris, Aymen I},
title = {Differential Effects of a First-in-Class IKKα Inhibitor on Trabecular and Cortical Bone in a Human Prostate Cancer Xenograft Model},
journal = {Calcified Tissue International},
year = {2026},
volume = {117},
number = {1},
doi = {10.1007/s00223-026-01558-y}
}
EUVIMED